Idaho to receive part of $300 million settlement with drugmaker Indivior
Pixabay
BOISE, Idaho (KIFI) - Attorney General Lawrence Wasden announced Idaho and other states have reached an agreement with Indivior plc and Indivior Inc. to settle allegations that the company falsely and aggressively marketed and promoted the drug Suboxone, resulting in improper expenditures of state Medicaid funds.
Suboxone is a drug approved for use by recovering opioid addicts to avoid or reduce withdrawal symptoms while they undergo treatment. Suboxone and its active ingredient, buprenorphine, are powerful and addictive opioids.
Indivior will pay $300 million to resolve various civil fraud allegations impacting Medicaid and other government healthcare programs. Idaho’s share is $95,019 and will be paid out over seven years. Approximately $38,000 will go to the state’s Medicaid program and $57,000 to the state’s general fund.
Reply
May 3, 2021
Attorney General William Tong today announced a $300 Million multistate settlement with Indivior plc and Indivior Inc. to settle allegations that Indivior falsely and aggressively marketed and otherwise promoted the drug Suboxone, resulting in improper expenditures of state Medicaid funds.
Subscribe
Indivior, a Delaware company, will pay a total of $300 million to resolve various civil fraud allegations impacting Medicaid and other government healthcare programs, of which $203,735,800 will go to Medicaid and $90,682,800 will be paid to the fifty states, plus Washington D.C. and Puerto Rico, as their share of the Medicaid recovery. Connecticut will receive $7,921,070.05 in the settlement and an additional $200,000 for Connecticut Department of Social Services state-funded programs.
Lynsey Mukomel
LANSING – Michigan Attorney General Dana Nessel announced today that Michigan will receive more than $4 million in a settlement agreement involving Indivior PLC and Indivior Inc. (Indivior).
This settlement covers six federal lawsuits and involves Indivior’s product Suboxone, a buprenorphine drug that was approved for use by recovering opioid addicts to avoid or reduce withdrawal symptoms while they undergo treatment.
Allegations detailed in lawsuits assert that, from 2010 through 2015, Indivior: promoted the sale and use of the drug to physicians who were writing prescriptions without having a medical purpose; knowingly promoted Suboxone Sublingual Film based on false and misleading claims that it was less subject to diversion and abuse than other buprenorphine products and less susceptible to accidental pediatric exposure than Suboxone Sublingual Tablets; and
SOM
AG Nessel Announces $300 Million Multistate Settlement with Suboxone MakerContact: Lynsey Mukomel 517-599-2746Agency: Attorney General
April 29, 2021
LANSING - Michigan Attorney General Dana Nessel announced today that Michigan will receive more than $4 million in a settlement agreement involving Indivior PLC and Indivior Inc. (Indivior).
This settlement covers six federal lawsuits and involves Indivior s product Suboxone, a buprenorphine drug that was approved for use by recovering opioid addicts to avoid or reduce withdrawal symptoms while they undergo treatment.
Allegations detailed in lawsuits assert that, from 2010 through 2015, Indivior:
promoted the sale and use of the drug to physicians who were writing prescriptions without having a medical purpose;